SPEC — SpectraCure AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK24.82m
- SEK26.10m
- SEK0.87m
Brief: SpectraCure New Treatment System Approved In UK For Use In Clinical Trial
Brief: SpectraCure: Patent Approved In Europe
Brief: Spectracure Q2 Net Loss Stable At SEK 7 Million
Brief: Spectracure Has Been Approved Grant From EU Of EUR 125,000
Brief: Spectracure Patent Approved In Europe
Brief: Spectracure Appoints Jörgen Wennberg As New Chairman
Brief: Spectracure Q4 Net Loss Widens To SEK 6.0 Mln
Brief: SpectraCure: Patent Approved In USA
Brief: SpectraCure Q3 Net Loss Widens To SEK 5.7 Million
Brief: Spectracure Q2 Net Loss Widens To SEK 7.0 Million
Brief: Spectracure Q1 Net Loss Widens To SEK 4.8 Million
Brief: SpectraCure: Johan Folkunger Appointed New CEO
Brief: SpectraCure Q4 Net Loss Widens To SEK 4.5 Mln
Brief: SpectraCure Q2 Net Loss Widens To SEK 4.8 Mln
Brief: SpectraCure Raises About SEK 140 Mln Through A Fully Subscribed Rights Issue
Brief: SpectraCure Files Patent Application For Protection Of New Technology
Brief: SpectraCure Q1 Net Loss Widens To SEK 3.8 Mln
Brief: Spectracure Carries Out Rights Issue Of About SEK 140 Mln
Brief: Spectracure FDA Has Approved Co's New Protocol For Clinical Trials